Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic SignaturesASX:GSS -1.49% EV-to-EBITDA is 1.44 as of Jul. 21, 2026. The stock has 4 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Genetic Signatures ranks better than 95.73% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Genetic Signatures's enterprise value is A$-14.32 Mil.
Genetic Signatures's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-9.94 Mil. Therefore, Genetic Signatures's EV-to-EBITDA for today is 1.44.
The historical rank and industry rank for Genetic Signatures's EV-to-EBITDA or its related term are showing as below:
ASX:GSS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -261.5 Med: -5.93 Max: 71.51
Current: 1.44
During the past 11 years, the highest EV-to-EBITDA of Genetic Signatures was 71.51. The lowest was -261.50. And the median was -5.93.
ASX:GSS's EV-to-EBITDA is ranked better than 95.73% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.55
vs ASX:GSS: 1.44
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genetic Signatures's PE Ratio (TTM) for today is calculated as:
Genetic Signatures's share price for today is A$0.066.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genetic Signatures's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.048.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Genetic Signatures's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:GSS vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Genetic Signatures's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Signatures EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Genetic Signatures's EV-to-EBITDA falls into.
Genetic Signatures's current Enterprise Value is A$-14.32 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genetic Signatures's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-9.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Signatures (ASX:GSS) has a EV-to-EBITDA of 1.44 as of Jul. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genetic Signatures. According to the industry distribution chart, Genetic Signatures ranks #5 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 4.3%.
Is Genetic Signatures' EV-to-EBITDA too high?
Genetic Signatures' current EV-to-EBITDA is 1.44. The Medical Diagnostics & Research industry median EV-to-EBITDA is 14.55. Genetic Signatures' value of 1.44 is 90.1% below this industry median. Based on the distribution chart, Genetic Signatures ranks #5 out of 117 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Genetic Signatures' EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Signatures ranks #5 out of 117 companies for EV-to-EBITDA. This places Genetic Signatures in the top 4% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.55. Genetic Signatures' value of 1.44 is 90.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.55, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetic Signatures's current EV-to-EBITDA of 1.44 is 90.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genetic Signatures. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Signatures's current EV-to-EBITDA is 1.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.38, compared to a current price of A$0.07 — trading 82.6% below its estimated fair value. The current EV-to-EBITDA is 1.44 and 90.1% below the Medical Diagnostics & Research industry median of 14.55. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current EV-to-EBITDA is 1.44 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:GSS has been successfully added to your 
